Clinical, Organizational, and Care Impact of the GetReady Digital Platform as a Clinical Decision Support Tool in the Follow-up of Patients With Cerebral Aneurysm

EQ-5D-5L visual analogue scale score at 12 months

Overall self-rated health status assessed using the EQ-5D-5L Visual Analogue Scale (VAS). The EQ VAS records the participant's self-rated health on a scale from 0 to 100, with higher scores indicating better perceived health.

Time frame: 12 months after enrollment

PPE-15 total score at hospital discharge or post-procedure assessment

Patient experience assessed using the Picker Patient Experience Questionnaire (PPE-15) in participants who undergo an intervention and hospital admission. The PPE-15 evaluates patient experience during inpatient care. The outcome will be reported as the PPE-15 total score.

Time frame: 30 days after hospital discharge - post diagnostic procedure and post-therapeutic procedure

Net Promoter Score reported by patients for the digital platform

Patient Net Promoter Score (NPS) for the use of the digital platform, calculated as the percentage of promoters (score 9-10) minus the percentage of detractors (score 0-6). Scores range from -100 to +100, with higher scores indicating greater likelihood to recommend the platform.

Time frame: 12 months after enrollment

Percentage of scheduled PROM and PREM questionnaires completed through the digital platform

Adherence to digital follow-up measured as the percentage of scheduled patient-reported outcome and patient-reported experience questionnaires completed through the digital platform during follow-up.

Time frame: Up to 12 months after enrollment

Percentage of participants remaining active on the digital platform at 12 months

Retention in digital follow-up measured as the percentage of enrolled participants who remain active users of the digital platform at 12 months.

Time frame: 12 months after enrollment

Mean number of in-person follow-up visits per therapeutic procedure within 90 days after treatment

Utilization of in-person follow-up will be assessed as the ratio of the total number of in-person visits (first visits plus follow-up visits within 90 days after treatment) divided by the number of therapeutic procedures performed during the same period.

Time frame: Within 90 days after therapeutic procedure

Number of participants readmitted within 30 days after discharge following aneurysm-related therapeutic intervention

Readmission will be assessed as the number of participants who, within 30 days after discharge following aneurysm-related therapeutic intervention, have a hospitalization episode associated with diagnosis code of intracranial aneurysm.

Time frame: Within 30 days after discharge following therapeutic intervention

Number of participants with post-procedural complications within 30 days after discharge following therapeutic intervention

Post-procedural complications will be assessed as the number of participants with readmission within 30 days after discharge and/or documentation of clinically relevant complications during follow-up, including subarachnoid hemorrhage when present.

Time frame: Within 30 days after discharge following therapeutic intervention

Mean length of hospital stay in days per therapeutic procedure

Length of stay will be calculated as the sum of hospital stay duration in hours divided by 24, and then divided by the total number of therapeutic procedures performed during the same period. The outcome will be reported as mean length of stay in days per therapeutic procedure.

Time frame: During the study period, up to January 2029